Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

ABIONYX Pharma Initiates Discussions With IRIS Pharma, a World Leader in Preclinical and Clinical Ophthalmology Research, With a View to a Possible Strategic Deal

BusinessWire_EN 
0 0 11.10.21
ABIONYX Pharma Initiates Discussions With IRIS Pharma, a World Leader in Preclinical and Clinical Ophthalmology Research, With a View to a Possible Strategic Deal: https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg
 

Regulatory News:

ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies, announced today that it is initiating discussions with IRIS Pharma, a world leader in preclinical and clinical ophthalmology contract research, with a view to a possible strategic deal, in which IRIS Pharma's contract research business would remain separate from the biotech research and development activity and to continue to grow.

These exchanges follow the positive clinical results which led to the disappearance of visual blur related to corneal deposits in a patient suffering from LCAT activity deficiency within the framework of a Temporary Use Authorization, and the initial preclinical results in uveitis that indicate the major therapeutic potential of bio-HDL in ophthalmology, and more broadly the role of lipids in ocular pathologies.

About ABIONYX Pharma

ABIONYX Pharma is a new generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005608/en/

Cerenis Therapeutics Holding S.A. Stock

€0.95
-0.420%
The price for the Cerenis Therapeutics Holding S.A. stock decreased slightly today. Compared to yesterday there is a change of -€0.004 (-0.420%).
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Cerenis Therapeutics Holding S.A. stock is not clear.
With a target price of 1 € there is a slightly positive potential of 5.82% for Cerenis Therapeutics Holding S.A. compared to the current price of 0.95 €.
Show more
Like: 0
Share
BusinessWire_EN 
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments

Not a member yet? Sign up for free!